Daunorubicin + Cytarabine + Venetoclax in de Novo AML

NAEnrolling by invitationINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2026

Conditions
Leukemia, Myeloid, AcuteAcute Myeloid Leukemia
Interventions
DRUG

(Daunorubicin, Cytarabine, Venetoclax)

"* Drugs:Daunorubicin~ * Dosage: 40 mg/(m²·d) on days 1 to 3~ * Other names: Cerubidine, Daunomycin, Rubidomycin~* Drugs:Cytarabine~ * Dosage: 100 mg/(m²·d) on days 1 to 5~ * Other names: Ara-C, Cytosine Arabinoside, Cytosar-U~* Drugs:Venetoclax~ * Dosage: 100 mg on day 1, 200 mg on day 2, and 400 mg from days 3 to 14~ * Other names: ABT-199, Venclexta, Venclyxto"

DRUG

(Daunorubicin, Cytarabine)

"* Drugs:Daunorubicin~ * Dosage: 60 mg/(m²·d) on days 1 to 3~ * Other names: Cerubidine, Daunomycin, Rubidomycin~* Drugs:Cytarabine~ * Dosage: 100 mg/(m²·d) on days 1 to 7~ * Other names: Ara-C, Cytosine Arabinoside, Cytosar-U"

Trial Locations (1)

230022

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei

All Listed Sponsors
collaborator

The First Affiliated Hospital of Anhui Medical University

OTHER

lead

Anhui Medical University

OTHER